ViroPharma Incorporated - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for ViroPharma Incorporated Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

ViroPharma Incorporated. The Group's principal activity is to develop and commercialize products that address serious diseases treated by physician specialists, in areas including hospital settings, transplant medicine and gastroenterology. It is focused on the marketing and sale of its commercialized product, Vancocin, an oral capsule to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The development activities are currently focused on product candidates to treat viral diseases including those caused by cytomegalovirus (CMV) and hepatitis C (HCV) infections. As on 21-Oct-2008, it acquired Lev Pharmaceuticals Inc.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report